RE: Point Biopharma1 Jul 2021 14:02
Sangijuelas1 From the below I read that it is only licensed to Avacta so its not their IP ,
Dr. William Bachovchin of Tufts University / Bach Biosciences developed the TME Targeting Technology and licensed it to Avacta Life Sciences, who subsequently branded the technology as pre | CISION™ (an Avacta trademark). POINT has secured a sub-licensing agreement with Bach Biosciences and Avacta that provides us the right to apply the technology to radiopharmaceuticals globally.